Oramed Pharmaceuticals (ORMP)
NASDAQ:ORMP
Want to see ORMP full AI Analyst Report?
Top Page
Oramed Pharm
(NASDAQ:ORMP)
Select Model
Select Model
Rating:59Neutral
Price Target:
$4.50
▲(54.64% Upside)
Action:Reiterated
Date:05/20/26
The score is held back primarily by weak operating performance and persistent cash burn despite a strong, low-leverage balance sheet. Technicals are supportive with a clear uptrend and positive momentum, while valuation appears low but is tempered by questionable earnings quality. Corporate actions are constructive, improving strategic optionality and monetization, but do not fully offset operational and cash-flow risks.
Positive Factors
Balance Sheet Strength
Extremely low leverage and sizable equity provide durable financial flexibility for a clinical-stage company. This conservatism supports solvency, allows funding of trials or selective M&A, and reduces short-term refinancing pressure, preserving strategic optionality over months.
Negative Factors
Weak Cash Generation
Persistent negative operating and free cash flow means the company cannot self-fund R&D or trials from operations. Continued cash burn forces reliance on financings or asset sales, increasing dilution risk and constraining strategic choices across the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Extremely low leverage and sizable equity provide durable financial flexibility for a clinical-stage company. This conservatism supports solvency, allows funding of trials or selective M&A, and reduces short-term refinancing pressure, preserving strategic optionality over months.
Read all positive factors
Oramed Pharm (ORMP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$163.30M
Dividend YieldN/A
Average Volume (3M)210.74K
Price to Earnings (P/E)0.9
Beta (1Y)0.55
Revenue Growth-100.00%
EPS GrowthN/A
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.65
Shares Outstanding40,926,083
10 Day Avg. Volume339,860
30 Day Avg. Volume210,739
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)59.00
P/FCF Ratio-10.65
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.44K
Enterprise Value/Ebitda1.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.26
Revenue Forecast (FY)N/A
Oramed Pharm Business Overview & Revenue Model
Company Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is ...
How the Company Makes Money
Oramed is a clinical-stage company; as such, its ability to generate recurring product revenue depends on successfully developing and commercializing its drug candidates. Historically, the company’s revenues, when present, have primarily come from...
Oramed Pharm Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
78
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Sep 2023 | Dec 2022 | Aug 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.00M | 0.00 | 1.34M | 2.70M | 2.70M |
| Gross Profit | 13.00K | -193.00K | 1.34M | 2.70M | 2.70M |
| EBITDA | 75.44M | -14.87M | 7.32M | -36.98M | -25.04M |
| Net Income | 64.05M | -19.10M | 5.53M | -37.76M | -22.24M |
Balance Sheet | |||||
| Total Assets | 230.86M | 155.28M | 220.55M | 161.64M | 128.00M |
| Cash, Cash Equivalents and Short-Term Investments | 125.89M | 141.93M | 162.05M | 155.72M | 94.14M |
| Total Debt | 825.00K | 372.00K | 51.62M | 894.00K | 533.00K |
| Total Liabilities | 31.12M | 9.93M | 57.66M | 10.49M | 11.48M |
| Stockholders Equity | 199.74M | 146.26M | 163.82M | 151.81M | 115.77M |
Cash Flow | |||||
| Free Cash Flow | -11.08M | -8.43M | -10.55M | -29.20M | -21.56M |
| Operating Cash Flow | -9.14M | -8.41M | -10.29M | -28.70M | -21.18M |
| Investing Cash Flow | 5.44M | 105.82M | -73.04M | 30.21M | -22.26M |
| Financing Cash Flow | -4.74M | -52.04M | 51.98M | 11.56M | 101.39M |
Oramed Pharm Technical Analysis
Positive
2.91
Price Trends
3.85
Positive
3.58
Positive
2.94
Positive
Market Momentum
0.11
Positive
47.91
Neutral
18.10
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORMP, the sentiment is Positive. The current price of 2.91 is below the 20-day moving average (MA) of 4.19, below the 50-day MA of 3.85, and below the 200-day MA of 2.94, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 47.91 is Neutral, neither overbought nor oversold. The STOCH value of 18.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORMP.
Oramed Pharm Risk Analysis
Oramed Pharm disclosed 45 risk factors in its most recent earnings report. Oramed Pharm reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oramed Pharm Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $163.30M | 0.90 | 60.96% | ― | -100.00% | ― | |
55 Neutral | $266.43M | -1.52 | -124.06% | ― | ― | 39.66% | |
54 Neutral | $222.04M | -2.69 | -79.63% | ― | -100.00% | -1124.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $140.57M | -1.83 | -155.40% | ― | -100.00% | 61.98% | |
43 Neutral | $17.93M | 0.04 | 7743.57% | ― | ― | 35.04% |
* Healthcare Sector Average
ORMP
Oramed Pharm
4.04
2.05
102.51%
WHWK
Whitehawk Therapeutics
4.77
2.97
165.00%
QNCX
Quince Therapeutics
1.20
-9.00
-88.24%
ALXO
ALX Oncology Holdings
1.93
1.48
328.89%
SPRB
Spruce Biosciences
51.81
46.94
963.86%
Oramed Pharm Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Oramed Completes Oratech Sale and Strategic Lifeward Financing
Positive
Apr 1, 2026
On March 25, 2026, Lifeward Ltd. completed its previously announced acquisition of Oramed’s wholly owned subsidiary Oratech Pharma, Inc., issuing Oramed more than 1.25 million Lifeward ordinary shares, over 1 million pre-funded warrants, and...
Business Operations and StrategyPrivate Placements and Financing
Oramed Pharmaceuticals Restructures Scilex Notes via Warrant Deal
Positive
Feb 20, 2026
On February 19, 2026, Oramed Pharmaceuticals entered into a Warrant Agreement with Scilex Holding Company, under which Oramed deferred an amortization payment due October 1, 2025 on Scilex’s Tranche B senior secured convertible notes in exch...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.